Chronic obstructive pulmonary disease (COPD) is the third-leading cause of death in the United States among people 65 years of age or older and the fourth-leading cause of death among people 45 to 65 years of age. Many patients with COPD are undiagnosed, and those who are diagnosed with COPD often are not receiving appropriate guideline-directed treatment. This webcast features expert discussion of the steps for appropriate diagnosis of COPD and guideline-directed COPD treatment, as well as considerations for appropriate selection of inhalation devices based on patient-specific factors.
After completing this activity, learners should be better able to:
- Implement steps to identify undiagnosed cases of COPD requiring treatment
- Apply guideline-recommended and evidence-based pharmacologic interventions to reduce COPD symptoms and decrease exacerbations
- Select appropriate inhalation device for patients with COPD based on patient characteristics
NPs and PAs
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Susan M. Tiso, DNP, APRN, FNP-BC, University of California, Irvine, Irvine, California
Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until September 14, 2023. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Daniel Thibodeau, DHSc, MHP, PA-C, Eastern Virginia Medical School, Norfolk, Virginia
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credits for learning and change.
This activity is supported by an educational grant from Mylan Specialty L.P., a Viatris Company.
Practicing Clinicians Exchange gratefully acknowledges Miller Medical Communications, LLC for their contributions as an educational partner for this program.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Fernando J. Martinez, MD, MS: consultant/advisor/speaker: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, CSL Behring, DevPro, GlaxoSmithKline, Hoffman-LaRoche, Lung Therapeutics, Novartis, Polarean, Pulmatrix, Pulmonx, Raziel, Sanofi, Sanofi/Regeneron, Shionogi, Teva, Theravance/Viatris, TwoXAR, United Therapeutics, Veracyte, Verona; independent contractor: Afferent/Merck, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Chiesi, DevPro BioPharma, GlaxoSmithKline, Nitto BioPharma, Patara/Respivant, Promedior/Roche, Sanofi/Regeneron, Veracyte; researcher: AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Chiesi, DevPro, Gilead Sciences, GlaxoSmithKline, Nitto, Novartis, Respivant, Roche, Sanofi/Regeneron; COPD Study Adjudication Committee: Medtronic.
Daniel Thibodeau, DHSc, MHP, PA-C: consultant/advisor/speaker: Arbor Pharmaceuticals.
Susan M. Tiso, DNP, APRN, FNP-BC has no relevant financial relationships to disclose.
None of the members of the Planning Committee or PCE staff have any relevant financial relationships to disclose, except Daniel Thibodeau, DHSc, MHP, PA-C, as noted above.
Participants wishing to earn CE/CME credit must:
- View the content in its entirety
- Relate the content material to the learning objectives
- Complete evaluation form
The estimated time to complete this activity is 1.00 hour.
Release date: September 15, 2022
Expiration date: September 14, 2023
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 105122C-7C